Targeting dendritic cells to treat multiple sclerosis.
Multiple sclerosis (MS) is considered to be a predominantly T-cell-mediated disease, and emerging evidence indicates that dendritic cells have a critical role in the initiation and progression of this debilitating condition. Dendritic cells are specialized antigen-presenting cells that can prime naive T cells and modulate adaptive immune responses. Their powerful biological functions indicate that these cells can be exploited by immunotherapeutic approaches. Therapies that inhibit the immunogenic actions of dendritic cells through the blockade of proinflammatory cytokine production and T cell co-stimulatory pathways are currently being pursued. Furthermore, novel strategies that can regulate dendritic cell development and differentiation and harness the tolerogenic capacity of these cells are also being developed. Here, we evaluate the prospects of these future therapeutic strategies, which focus on dendritic cells and dendritic cell-related targets to treat MS.
Comabella
Manuel
M
Multiple Sclerosis Center of Catalonia, Vall d'Hebron University Hospital, Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Montalban
Xavier
X
Münz
Christian
C
Lünemann
Jan D
JD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D002454:Cell Differentiation / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology
D000911:Antibodies, Monoclonal; D016207:Cytokines